Tourmaline Bio Inc. (TRML NASDAQ) stock market data APIs
$16.0494
-0.24(-1.5%)
as of July 2, 2025
Try our APIs with
free plan!
Tourmaline Bio Inc. Financial Data Overview
Price chart is built with
Anychart
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Prev. Close
16.0494
Open
15.8052
High
16.5926
Low
15.4071
52 wk Range
11.56-29.788
Market Cap
407 M
Shares Outstanding
25 689 K
EPS
-0.89
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tourmaline Bio Inc. data using free add-ons & libraries
Get Tourmaline Bio Inc. Fundamental Data
Tourmaline Bio Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -98 405 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.9363
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tourmaline Bio Inc. News
New
H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results
On May 27, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio, Inc. (NASDAQ:TRML) while keeping the price target at $50. This comes after the company released promising results ...
BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)
On Wednesday, May 21, BMO Capital Markets reaffirmed its “Outperform” rating on Tourmaline Bio, Inc. (NASDAQ:TRML) with a price target of $35. The firm believes that the market’s negative react...
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve t...
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tou...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
